1. Home
  2. GMM vs IFRX Comparison

GMM vs IFRX Comparison

Compare GMM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Mofy Metaverse Limited

GMM

Global Mofy Metaverse Limited

HOLD

Current Price

$1.28

Market Cap

38.4M

Sector

N/A

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.10

Market Cap

86.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GMM
IFRX
Founded
2017
2007
Country
China
Germany
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.4M
86.0M
IPO Year
2023
2017

Fundamental Metrics

Financial Performance
Metric
GMM
IFRX
Price
$1.28
$1.10
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.50
AVG Volume (30 Days)
17.4K
7.7M
Earning Date
08-18-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.79
N/A
Revenue
$48,171,048.00
$73,729.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,075.42
P/E Ratio
$0.72
N/A
Revenue Growth
41.74
N/A
52 Week Low
$1.23
$0.71
52 Week High
$4.97
$2.82

Technical Indicators

Market Signals
Indicator
GMM
IFRX
Relative Strength Index (RSI) 22.45 43.80
Support Level $1.23 $0.92
Resistance Level $1.59 $1.28
Average True Range (ATR) 0.09 0.11
MACD -0.02 -0.02
Stochastic Oscillator 10.47 36.50

Price Performance

Historical Comparison
GMM
IFRX

About GMM Global Mofy Metaverse Limited

Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: